Abstract
Objective: Fondaparinux sodium is the first of a new class of antithrombotic agents: the selective factor Xa inhibitors. Coadministration with digoxin may occur in clinical practice and both drugs are excreted almost completely by the renal route. In this study we assessed the possible pharmacokinetic and pharmaco-dynamic interaction of fondaparinux sodium with digoxin at steady state in healthy male volunteers.
Design: In a phase I randomised, crossover study, volunteers (n = 24) were treated in two periods. The first period was once-daily administration of fondaparinux sodium 10mg subcutaneously alone for 7 days; the second period was 7 days of digoxin 0.25mg orally alone followed by 7 days of coadministration with fondaparinux sodium 10mg. Each period was separated by a washout of 12 days.
Methods: Urinary volumes, plasma concentration-time profiles and non-compartmental pharmacokinetic parameters of fondaparinux sodium and digoxin were obtained at steady state, following administration alone or together for each period. A bioequivalence approach was taken to assess interaction. Pharmaco-dynamic parameters were supine blood pressure and heart rate and the ECG parameters PR interval, QRS interval, QT interval and QTc. The safety of the treatments was monitored.
Results and Conclusions: The pharmacokinetic profiles of both digoxin and fondaparinux sodium were unaffected by coadministration. Bioequivalence was concluded, based on the 90% confidence intervals of the ratio of adjusted geometric means calculated for the 2-by-2 comparison of peak concentration, area under the concentration-time curve and cumulative urinary excretion, which lay within the 0.80 to 1.25 reference interval. There were no clinically significant fluctuations in vital signs and ECG parameters. The coadministration of digoxin with fondaparinux sodium was well tolerated and no significant changes were observed in vital signs.
Similar content being viewed by others
References
Lormeau JC, Herault JP. The effect of the synthetic fondaparinux SR90107/Org31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995; 74: 1474–7
Keam SJ, Goa KL. Fondaparinux sodium. Drugs 2002; 62(11): 1673–85
Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic fondaparinux sodium with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492–9
Olson ST, Björk I, Sheffer R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of anti-thrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528–38
Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Phar-macokinet 2002; 41 Suppl. 2: 1–9
Turpie AG, Gallus AS, Hoek JA. Pentasaccharide Investigators: a synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619–25
Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thrombo-embolism after elective major knee surgery. N Engl J Med 2001; 345: 1305–10
Bauer K, and the Pentasaccharide Orthopaedic Prophylaxis Studies Investigators. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR90107A versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective major knee surgery: the Pentamaks study [abstract]. Thromb Haemost 2001; 86 Suppl.: OC46
Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715–20
Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721–6
Paolucci F, Clavies M-C, Donat FA, et al. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002; 41 Suppl. 2: 11–18
Lieu C, Shi J, Donat FA. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 2002; 41 Suppl. 2: 19–26
Diot C. Determination of digoxin concentration in human plasma samples. Poitiers, France: CEPHAC. Cephac Study Code: SOP No. 761, version b; Study Report No.: CSRBDY-INT3933-EN-E01
Diot C. Determination of digoxin concentration in human urinary samples. Poitiers, France: CEPHAC. Cephac Study Code: SOP No. 930, version a; Study Report No.: CSRBDY-INT3933-EN-E01
Adamson H, Jacobs A, Warrington S. Normal values for electrocardiogram intervals in young healthy subjects. Int J Pharm Med 1998; 12: 289–91
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mant, T., Fournié, P., Ollier, C. et al. Absence of Interaction of Fondaparinux Sodium with Digoxin in Healthy Volunteers. Clin Pharmacokinet 41 (Suppl 2), 39–45 (2002). https://doi.org/10.2165/00003088-200241002-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200241002-00006